Answers are grounded in this paper and cite their sources.
Extramammary Paget's disease (EMPD) is a rare cutaneous malignancy for which evidence regarding stage-specific prognosis and treatment outcomes remains limited. We retrospectively analyzed 104 patients with EMPD treated at a single Japanese institution between November 2012 and December 2025. Progression-free survival (PFS), overall survival (OS), and treatment responses were evaluated. The cohort comprised 56 patients with Stage 0, 23 with Stage I, 11 with Stage II, seven with Stage III, six with Stage IV, and one with unclassified disease. Both PFS and OS decreased significantly with advancing stage (log-rank test, both p < 0.0001). Eleven patients with residual or recurrent ill-defined lesions or who declined surgery received topical imiquimod. Five patients achieved a complete response, corresponding to a complete response rate of 45.5% (95% confidence interval [CI], 16.7%-76.6%); three had non-CR/non-PD, and the remaining three had PD, manifesting as local progression and/or lymph node metastasis. Eleven patients with Stage IV disease or distant recurrence received systemic therapy. Docetaxel was the most frequently used first-line regimen and achieved an overall response rate of 60.0% (3/5; 95% CI, 14.7%-94.7%), although treatment discontinuation due to adverse events was common. None of the three patients who received second-line nivolumab achieved an objective response. These findings demonstrate a marked deterioration in prognosis with advancing EMPD stage. Imiquimod may provide clinical benefit in carefully selected patients with ill-defined lesions who are unsuitable for surgery, whereas currently available systemic therapies have limited durability and tolerability. Larger multicenter prospective studies are warranted to establish optimal treatment strategies for EMPD.
No takes yet. Share an insight, caveat, or question.
Takahashi‐Watanabe et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: